Hyperinsulinaemia as long-term predictor of death and ischaemic heart disease in nondiabetic men: The Malmö Preventive Project

Journal of Internal Medicine

Volumn 253, Issue 2, 2003, Pages 136-145

  Nilsson, Peter ^a   Nilsson, J A ^a   Hedblad, B ^a   Eriksson, K F ^a   Berglund, G ^a  

^a LUND UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Cardiovascular; Epidemiology; Insulin; Mortality; Obesity; Risk factors

Indexed keywords

GLUCOSE; INSULIN;

ADULT; ARTICLE; CARDIOVASCULAR DISEASE; CIGARETTE SMOKING; CORONARY ARTERY DISEASE; GLUCOSE BLOOD LEVEL; HUMAN; HYPERINSULINEMIA; HYPERLIPIDEMIA; HYPERTENSION; INSULIN BLOOD LEVEL; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; MORTALITY; OBESITY; ORAL GLUCOSE TOLERANCE TEST; PRIORITY JOURNAL; RISK ASSESSMENT; RISK FACTOR;

ADULT; BLOOD GLUCOSE; FEMALE; FOLLOW-UP STUDIES; HUMANS; HYPERINSULINISM; INSULIN; MALE; MIDDLE AGED; MYOCARDIAL ISCHEMIA; RISK FACTORS; SURVIVAL RATE; SWEDEN;

EID: 0037322198     PISSN: 09546820     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2796.2003.01064.x     Document Type: Article

References (54)

1. Reaven G. Role of insulin resistance in human disease. Diabetes 1988; 37: 1595-607.
2. Pyörälä K, Savolainen S, Kaukola S, Haapakoski J. Plasma insulin as a coronary heart disease risk factor: relationship to other risk factors and predictive value during 91/2 years follow up of the Helsinki policemen study population. Acta Med Scand 1985; 701 (Suppl.): 38-52.
3. Ducimetiere P, Eschwege E, Papoz L, Richard JL, Claude JR, Rosselin G. Relationship of plasma insulin levels to the incidence of myocardial infarction and coronary heart disease mortality in a middle-aged population. Diabetologia 1980; 19: 205-10.
4. Fontbonne A, Charles MA, Thibault N et al. Hyperinsulinaemia as a predictor of coronary heart disease mortality in a healthy population: The Paris Prospective Study, 15-year follow up. Diabetologia 1991; 34: 356-61.
5. Welborn TA, Wearne K. Coronary heart disease incidence and cardiovascular mortality in Busselton with reference to glucose and insulin concentrations. Diabetes Care 1979; 2: 154-60.
6. Möller LF, Jepsersen J. Fasting serum insulin levels and coronary heart disease in a Danish cohort: 17-year follow-up. J Cardiovasc Risk Factors 1995; 2: 235-40.
7. Després JP, Lamarche B, Mauriège P et al. Hyperinsulinemia as an independent risk factor for ischaemic heart disease. N Engl J Med 1996; 334: 952-7.
8. Perry IJ, Wannamethee SG, Whincup PH, Shaper GA, Walker MK. Aberti KGMM. Serum insulin and incident coronary heart disease in middle-aged British men. Am J Epidemiol 1996; 144: 224-34.
9. Lakka H-M, Lakka TA, Tuomilehto J, Sivenius J, Salonen JT. Hyperinsulinaemia and the risk of cardiovascular death and acute coronary and cerebrovascular events in men. The Kuopio Ischaemic Heart Disease Risk Factor Study. Arch Intern Med 2000; 160: 1160-8.
10. Folsom AR, Szklo M, Stevens J, Liao F, Smith R, Eckfeldt JH. A prospective study of coronary heart disease in relation to fasting insulin, glucose and diabetes: the Atherosclerosis Risk in Communities (ARIC) study. Diabetes Care 1997; 20: 935-42.
11. Jarrett RJ. Why is insulin not a risk factor for coronary heart disease? Diabetologia 1994; 37: 945-7.
12. Wingard DL, Barrett-Connor EL, Ferrara A. Is insulin really a heart disease risk factor? Diabetes Care 1995; 18: 1299-304.
13. McKeigue P. Association between insulin levels and cardiovascular disease are confounded by comorbidity. Diabetes Care 1995; 18: 1294-8.
14. Ferrara A, Barrett-Connor EL, Edelstein SL. Hyperinsulinemia does not increase the risk of fatal cardiovascular disease in elderly men or women without diabetes: The Rancho Bernardo Study, 1984-91. Am J Epidemiol 1994; 140: 857-69.
15. Welin L, Eriksson H, Larsson B, Ohlson LO, Svärdsudd K, Tibblin G. Hyperinsulinemia is not a major coronary risk factor in elderly men. The study of men born in 1913. Diabetologia 1992; 35: 766-70.
16. Kuusisto J, Mykkänen L, Pyörälä K, Laakso M. Hyperinsulinemic microalbuminuria. A new risk factor for coronary heart disease. Circulation 1995; 91: 835-7.
17. Ruige JB, Assendelft WJJ, Dekker JM, Kostense PJ, Heine RJ, Bouter LM. Insulin and risk of cardiovascular disease. Circulation 1998; 97: 996-1001.
18. Pyörälä M, Miettinen H, Laakso M, Pyörälä K. Plasma insulin and all-cause, cardiovascular, and non-cardiovascular mortality. Diabetes Care 2000; 23: 1097-102.
19. Pyörälä M, Miettinen H, Halonen P, Laakso M, Pyörälä K. Insulin resistance syndrome predicts the risk of coronary heart disease and stroke in healthy middle-aged men: the 22-year follow-up results of the Helsinki Policemen Study. Arterioscler Thromb Vasc Biol 2000; 20: 538-44.
20. Trell E. Community-based preventive medical department for individual risk factor assessment and intervention in an urban population. Prev Med 1983; 2: 397-402.
21. Alberti KGMM, Zimmet P, for the WHO Consultation Group. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: Diagnosis and classification of diabetes mellitus. Diabetic Med 1998; 15: 539-53.
22. Berglund G, Eriksson KF, Israelsson B et al. Cardiovascular risk groups and mortality in an urban Swedish male population: the Malmö Preventive Project. J Intern Med 1996; 239: 489-97.
23. Eriksson K-F, Lindgärde F. Impaired glucose tolerance in a middle-aged male urban population: a new approach for identifying high risk cases. Diabetologia 1990; 33: 526-31.
24. Berglund G, Nilsson P, Hedblad B et al. Long-term outcome of the Malmö Preventive Project. Total mortality and cardiovascular morbidity. J Intern Med 2000; 244: 19-29.
25. Heding LG. A simplified insulin radioimmunoassay method. In: Donato L, Milhaud G, Sirchis I, eds. Labelled Proteins in Tracer Studies. Brussels: Euratom, 1966; pp. 345-50.
26. Hansen O, Johansson BW. Epidemiological aspects of coronary heart disease in Malmö, Sweden, 1935-88. Am J Epidemiol 1991; 133: 721-33.
27. International Classification of Disease Nineth Edition (ICD-9). Swedish edition, Stockholm, 1986.
28. SAS. SAS. Ver. 6. 12. Cary, NC, USA: SAS Inc., 1998.
29. Laakso M. How good a marker is insulin levels for insulin resistance? Am J Epidemiol 1993; 137: 959-65.
30. Ferranninni E. Insulin resistance and hyperinsulinaemia: why are they important? Curr Opp Endocrinol Diab 1999; 6 (Suppl. 1): S13-S16.
31. DeFronzo R, Feranninni E. Insulin resistance: a multifaceted syndrome responsible for NIDDM. obesity, hypertension, dyslipidemia, and atherosclerotic disease. Diabetes Care 1991; 14: 173-94.
32. Nagi DK, Hendra TJ, Ryle AJ, Yudkin JS. The relationships of concentration of insulin, intact proinsulin and 32-33 split proinsulin with cardiovascular risk factors in type II (non-insulin-dependent) diabetic subjects. Diabetologia 1990; 33: 532-7.
33. Modan M, Halkin H, Lusky A, Segal P, Fuch Z, Chetrit A. Hyperinsulinaemia is characterized by jointly disturbed plasma VLDL, LDL, and HDL levels. A population-based study. Arteriosclerosis 1988; 8: 227-36.
34. Stout R. Insulin and atheroma, a 20-year perspective. Diabetes Care 1990; 13: 631-54.
35. Reaven GM, Laws A. Insulin resistance, compensatory hyperinsulinaemia, and coronary heart disease. Diabetologia 1994; 37: 948-52.
36. Godsland IF, Stevensson JC. Insulin resistance: syndrome or tendency? Lancet 1995; 348: 100-3.
37. Eliasson M, Nilsson P, Jansson J-H. Increased levels of tissue plasminogen activator antigen in essential hypertension - A population-based study in Sweden. J Hypertens 1997; 15: 349-56.
38. Björntorp P. 'Portal' adipose tissue as a generator of risk factors for cardiovascular disease and diabetes. Arteriosclerosis 1990; 10: 493-6.
39. Björntorp P. Metabolic implications of body fat distribution. Diabetes Care 1991; 14: 1132-43.
40. Yudkin JS, Kumari M, Humphries SE, Mohamed-Ali V. Inflammation, obesity, stress and coronary heart disease: is interleukin-6 the link? Atherosclerosis 2000; 148: 209-14.
41. Mayer EJ, Newman B, Austin MA et al. Genetic and environmental influences on insulin levels and the insulin resistance syndrome: an anlysis of women twins. Am J Epidemiol 1996; 143: 323-32.
42. Hong Y, Pedersen NL, Brismar K, de Faire U. Genetic and environmental architechture of the features of the insulin-resistance syndrome. Am J Hum Genet 1997; 60: 143-52.
43. Fontbonne A. Why can high insulin levels indicate a risk for coronary heart disease? Diabetologia 1994; 37: 953-5.
44. Hill AB. The enviroment and disease: association or causation? Proc R Soc Med 1965; 58: 295-300.
45. Nolan JJ, Ludvik B, Beerdsen P, Joyce M, Olefsky J. Improvement in glucose tolerance and insulin resistance in obese subjects treated with troglitazone. N Engl J Med 1994; 331: 1188-93.
46. Schoonjans K, Auwerx J. Thiazolidinediones: an update. Lancet 2000; 355: 1008-10.
47. Matthaei S, Stumvoll M, Kellerer M, Häring HU. Pathophysiology and pharmacological treatment of insulin resistance. Endocr Rev 2000; 21: 585-618.
48. Bonora E, Willeit J, Kiechl S et al. U-shaped and J-shaped relationships between serum insulin and coronary heart disease in the general population. The Bruneck Study. Diabetes Care 1998; 21: 221-30.
49. Balkan B, Eshwège E. Insulin resistance: an independent risk factor for cardiovascular disease? Diabetes, Obesity Metabolism 1999:1 (Suppl. 1): S23-S31.
50. Lindahl B, Dinesen B, Eliasson M et al. High proinsulin concentration precedes acute myocardial infarction in a non-diabetic population. Metabolism 1999; 48: 1197-202.
51. Yudkin JS, May M, Elwood P, Yarnell JWG, Greenwood R, Davey Smith G. Concentrations of proinsulin like molecules predict coronary heart disease risk independently of insulin: prospective data from the Caerphilly Study. Diabetologia 2002; 45: 327-36.
52. Zethelius B, Byberg L, Hales CN, Lithell H, Berne C. Proinsulin is an independent predictor of coronary heart disease: report from a 27-year follow-up study. Circulation 2002; 105: 2153-8.
53. Tuomilehto J, Lindstrom J, Eriksson JG et al. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med 2001; 344: 1343-50.
54. Knowler WC, Barrett-Connor E, Fowler SE et al. Diabetes Prevention Program Research Group. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002; 346: 393-403.